Shruti Sridhar

Shruti Sridhar

Auto-generated profile, based on publicly available information

Shruti Sridhar

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Cancers often overexpress multiple clinically relevant oncogenes, but it is not known if combinations of oncogenes in cellular subpopulations within a cancer influence clinical outcomes. Using quantitative multispectral imaging of the prognostically relevant oncogenes MYC, BCL2, and BCL6 in diffuse large B-cell lymphoma (DLBCL), we show that the percentage of cells with a unique combination MYC+BCL2+BCL6− (M+2+6−) consistently predicts survival across four independent cohorts (n = 449), an effect not observed with other combinations including M+2+6+. We show that the M+2+6− percentage can be mathematically derived from quantitative measurements of the individual oncogenes and correlates with survival in IHC (n = 316) and gene expression (n = 2,521) datasets. Comparative bulk/single-cell transcriptomic analyses of DLBCL samples and MYC/BCL2/BCL6-transformed primary B cells identify molecular features, including cyclin D2 and PI3K/AKT as candidate regulators of M+2+6− unfavorable biology. Similar analyses evaluating oncogenic combinations at single-cell resolution in other cancers may facilitate an understanding of cancer evolution and therapy resistance. Significance: Using single-cell–resolved multiplexed imaging, we show that selected subpopulations of cells expressing specific combinations of oncogenes influence clinical outcomes in lymphoma. We describe a probabilistic metric for the estimation of cellular oncogenic coexpression from IHC or bulk transcriptomes, with possible implications for prognostication and therapeutic target discovery in cancer. This article is highlighted in the In This Issue feature, p. 1027

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Prognostic significance of subpopulations after R-CHOP therapy. A, Pooled univariate Cox PH model analysis for MYC, BCL2, and BCL6 single oncogene and subpopulations percentage extent as predictors of OS across multiple DLBCL cohorts. Percentage extent was used as a continuous variable in the model at 5% increments (see Survival Analysis) for an unbiased comparison between the variables. Pooled P values were Bonferroni corrected for single oncogenes and subpopulations independently to adjust for multiple testing and are shown for each variable. Hazard ratio (HR) with 95% confidence interval (CI) per 5%-positivity increment is shown (see also Supplementary Table S4). B, Kaplan–Meier OS analysis of dichotomized into M+2+6− high and low groups. Log-rank test, shading denotes 95% CI. An optimal dichotomization cutoff was used for stratification; total patient numbers in each group are shown.

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Validation of prognostic significance of the M+2+6− subpopulation metric in gene-expression datasets. A, Distribution of single oncogene positivity in DLBCL cohorts as assessed by mfIHC (see Supplementary Fig. S9A and S9B). B, Impact of subpopulation metrics in GEP datasets on OS. Pooled univariate Cox PH model analysis; metric was used as a continuous variable in the model at 5% increments. HR per 5% increment with 95% CI is shown; CI are proportional on both tails but are capped at the graph's edges. Pooled P values were Bonferroni corrected to adjust for multiple testing and are shown for each subpopulation. C, Kaplan–Meier OS analysis of GEP cohorts stratified uniformly across absolute 15% M+2+6− metric into -high and -low groups. Log-rank test, shading denotes 95% CI. Total patient numbers in each group are shown. CMMC, Chi-Mei Medical Center.

18 April 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Supplementary table 1. Per-patient mfIHC MYC, BCL2 and BCL6 single oncogene and subpopulation scores for normal tonsil tissue and reactive lymph node tissue. Supplementary table 2. Per-patient mfIHC MYC, BCL2 and BCL6 single oncogene and subpopulation scores for DLBCL tissue (NUH, CMMC, SGH, MDA, BCA and UP). Supplementary table 6. Inferred percentage extents of MYC, BCL2, BCL6 and sub-population metrics in GEP cohorts. Supplementary table 11. Correlation of M+2+6- metric with gene expression in GEP cohorts. Supplementary table 12. Differential gene expression analysis of primary germinal center (GC) B-cells with M+2+ and M+2+6+ overexpression. Supplementary table 13. Differentially expressed genes between M+2+6- and all other malignant cells in scRNA-seq samples of DLBCL. Dichotomized non-parametric comparison, Wilcoxon rank sum test. Supplementary table 14. Analysis of positive enrichment of Wikipathways terms between M+2+6- and all other malignant cells in scRNA-seq samples of DLBCL by gprofiler2.

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
Evaluation of M+2+6− cells in scRNA-seq datasets of DLBCL. A, Uniform Manifold Approximation and Projection (UMAP) of malignant B cells from the Roider and Steen cohorts. B, Proportion of subpopulations across samples and annotation of M+2+6− cells in UMAP. C, Correlation of genes enriched in the M+2+6− subpopulation as evaluated by scRNA-seq with hits from the bulk GEP cohorts (Fig. 5E). CCND2 is highlighted and is among the concordant hits (see also Supplementary Table S13). D, WikiPathways terms enrichment among genes positively associated with M+2+6− cells. Both axes in C and D are scaled exponentially for clarity (see also Supplementary Table S14).

4 May 2023
Verified
Other
Open access
MHMichal Marek Hoppe
Michal Marek Hoppe
PJPatrick Jaynes
Patrick Jaynes
FSFan Shuangyi
Fan Shuangyi
YPYanfen Peng
Yanfen Peng
SSShruti Sridhar
Shruti Sridhar
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
MYC, BCL2, and BCL6 protein coexpression in DLBCL can be inferred from individual marker data. A, Schematic of possible relationships between expression of three oncogenes in a population of cells. The distribution of these oncogenes can either reflect interdependent expression, independent/stochastic expression, or mutually exclusive expression. These relationships result in the percentage extent of oncogenes in the tumor being either strongly positively correlated, not correlated, or strongly negatively correlated, respectively. Created with BioRender.com. B, Correlation of MYC, BCL2, and BCL6 percentage extent across patients in DLBCL cohorts. Spearman correlation; axes are equivalent in all panels. C, Good correlation between probabilistically predicted subpopulation percentage extent based on single oncogene positivity and observed percentage extent in the NUH cohort. Cases of double-hit lymphoma (DHL, MYC+BCL2+ translocations or MYC+BCL6+ translocations) or triple-hit lymphoma (THL) are highlighted. Spearman rho for each correlation is shown; axes are equivalent in all panels. Correlation for other cohorts can be found in Supplementary Fig. S7. D, Prospective evaluation of an optimal dichotomization cutoff for M+2+6− percentage extent in the BCA cohort. Univariate Cox PH model at 1% extent positivity increment, HR for death with 95% CI. HR scale is exponential. Optimal dichotomization cutoff is highlighted in blue. E, Kaplan–Meier OS analysis of the chromogenic IHC BCA cohort evaluation stratified into M+2+6− metric high and low groups across an absolute value of 15% M+2+6−metric. Log-rank test, shading denotes 95% confidence interval. CMMC, Chi-Mei Medical Center.